Tau imaging is a brain PET scan that maps tau tangles, twisted proteins tied to Alzheimer's damage. For patients with memory loss, it improves detection and staging but applies only to cognitively impaired adults with unresolved access and diversity gaps.
Lantheus announced Aug. 14, 2026, FDA approval of Tauklarify for brain PET in adults with cognitive impairment being evaluated for Alzheimer's disease FDA approval notice. In practice, clinics pair the scan with exams, cognitive testing, and amyloid results to guide care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the new scan shows
- How accurate is the new tracer?
- Who qualifies and who does not
- What gaps affect care now
What the new scan shows
The scan identifies tau neurofibrillary tangle pathology, the clumps that track with Alzheimer's progression. It helps stage tau burden, meaning how far tau has spread beyond early memory areas into neocortex. Neocortex is the outer brain layer used for thinking and planning.
For memory clinics, that staging helps clarify Alzheimer's versus non-Alzheimer's impairment when history and amyloid results leave doubt. A scan with spread into neocortex points more toward Alzheimer's-related impairment, while a negative scan argues against it. Doctors still start with clinical evaluation and use blood tests, PET, or spinal fluid only for confirmation or uncertain cases.
How accurate is the new tracer?
NeurologyLive reported two blinded-read studies in 500+ participants across five readers blinded-read results. Positive agreement was 68% to 88%, while negative agreement was 93% to 99%. Positive agreement means the share of tau-positive cases read as positive. Negative agreement means the share of tau-negative cases read as negative. Interreader agreement was strong, with Fleiss kappa of 0.92 and 0.86, a measure of reader consistency. Medscape reported the HEAD study compared both tracers in 682 people with paired scans plus amyloid PET and cognitive testing HEAD study report.
MK-6240 separated Alzheimer's-related impairment better than flortaucipir, with area under the curve 0.93 versus 0.86. Area under the curve means overall ability to separate groups. MK-6240 flagged neocortical tau in 28% versus 16% of cognitively impaired participants. In amyloid-positive people without impairment, it found medial temporal lobe tau in 15% versus 6%. The medial temporal lobe is an early memory hub. This earlier signal may flag people on the Alzheimer's pathway who may benefit from anti-amyloid therapy.
Who qualifies and who does not
The label limits use to Alzheimer's evaluation in adults who already have cognitive impairment. It is not for screening people without symptoms.
Safety and effectiveness are not established for non-Alzheimer's tauopathies. Tauopathies are other diseases that also involve tau. Ask the clinic whether your symptoms and workup fit the labeled use before scheduling.
- adult with measured cognitive impairment
- doctor is evaluating Alzheimer's disease as the cause
- result will stage tau or clarify an uncertain diagnosis
What gaps affect care now
The HEAD cohort was 55% women and 93% White, so results may not reflect all clinic populations. Many blood tests do not meet accuracy thresholds, so blood results alone cannot replace careful workup.
Access, radiation exposure, cost, and standard methods for quantitative reads remain unresolved for routine clinic use. Guidance still requires clinical evaluation first and reserves PET or spinal fluid for confirmation or uncertain cases. Ask what read method your center uses, what cost and radiation to expect, and how the result will change your care plan.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Accuracy, Limits, and Evidence Gaps for Memory Clinic Patients
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Accuracy, Limits, and Evidence Gaps for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Accuracy, Limits, and Evidence Gaps for Memory Clinic Patients
